UNSPSC 51371701: Narceine

This classification denotes an opioid receptor agonist with the molecular formula C23H27NO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CTT09X2F1M, chemically known as 2,3-dimethoxy-6-((6-(2-dimethylaminoethyl)-2-methoxy-3,4-methylendioxyphenyl)acetyl)benzosaeure but generally known as narceine, which bears US NIH Compound Identifier 8564. European Medicines Agency schedules Narceine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22705.

Most nations schedule narceine under HS 29391900 and SITC 54141. As of Q4 2014, NARCEINE remains the US FDA Preferred Term for this commodity. Narceine bears US NLM identifiers UMLS ID C2984004 and NCI Concept Code C91050. SMILES: O1C2C(OC)C(C(CCN(C)C)CC2OC1)CC(=O)C1C(C(OC)C(OC)CC1)C(=O)O.

UNSPSC 51371701 Narceine, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The recent opportunities show instead that state and local governments are procuring naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—none of which are narceine, an opium alkaloid with minimal or no legitimate pharmaceutical use in modern medical practice. The mismatch between the code's nominal scope and the work actually being solicited suggests this code does not capture meaningful state and local procurement activity in its intended product category.

The three recent opportunities span different purchasing models and issuing bodies: Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (due July 26, 2023); the Texas Health and Human Services Commission issued an RFI for direct-to-manufacturer prescription program capabilities (response deadline April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon, with proposals due March 26, 2026. Activity is concentrated in Florida, Texas, and Minnesota. Given the absence of actual narceine procurement in state and local solicitations and the apparent tagging error in the source data, this code warrants monitoring for correction or retagging rather than active pursuit at this time.